
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.

Jennifer Lim, MD, FARVO, FASRS, gives an update on the phase 2 DAVIO 2 trial comparing EYP-1901 with aflibercept at the annual ASRS meeting in Stockholm, Sweden.

Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.

Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Data in early-stage patients was presented at 42nd American Society of Retina Specialists Annual Scientific Meeting, being held in Stockholm, Sweden.

The purpose of the study was to determine if experience affects the surgeons’ dexterity response to pharmacologic and behavioral interventions.

Carl C Awh, MD, FASRS, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss the first readout of the Phase 3 PAGODA trial at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Theodore Lang, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Martin Zinkernagel, MD, PhD, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss his time on the sustainability expert panel Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Srinivas Sai Kondapalli, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the predictive role of outer retinal tubulations in lesion growth for subfoveal and non subfoveal geographic atrophy at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

6E10 combined with local prophylaxishas been selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks.

Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Attendees shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.


IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

Presenters from around the world converge on the Pacific Northwest to highlight innovation.

Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.

Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.

Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.